Order

Researchers Discover Gene For Rare Skin Disorder

WASHINGTON, June 20, 2007-Researchers funded in part by theNational Institutes of Health have identified the gene thataccounts for most cases of Goltz syndrome, a rare skin disorderthat can also affect bone and eye development. The cases appear to result from a defect in the gene known asPORCN, which contains the information needed to make a protein,referred to by researchers as porcupine...

Remarks by President Bush on Stem Cell Veto and Executive Order

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- Thefollowing is a transcript of remarks by President Bush on stem cellveto and executive order: THE PRESIDENT: Welcome. I'm glad you're here. America is anation that leads the world in science and technology. Ourinnovative spirit is making possible incredible advances inmedicine that could sa...

IMPAX Presents at Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders

HAYWARD, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - IMPAX Laboratories,Inc. (OTC:IPXL) today announced that two poster presentations,highlighting the company's compound, IPX054, a combined immediate-and extended-release carbidopa/levodopa (CD/LD) product to bemarketed as VADOVA(TM), were presented at the Movement DisorderSociety's 11th International Congress of Parkinson's Disease andMovement D...

International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinson's Disease

Results presented at the Movement Disorder Society's 11thInternational Congress in Istanbul, Turkey KANSAS CITY, Mo., June 08, 2007 /PRNewswire-FirstCall/ -- Newinformation on the use of AZILECT(R) (rasagiline tablets) for thetreatment of Parkinson's disease (PD) was reported this week at TheMovement Disorder Society's congress in Istanbul, Turkey.Once-daily AZILECT was approved by the FD...

Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease Presented at International Congress of Parkinson's Disease and Movement Disorders

Faust's lead molecule, FP0011, exhibited a differentiatedcombination of therapeutic effects and good tolerance in mid- tolate-stage patients STRASBOURG, France, June 6, 2007 - Faust Pharmaceuticals S.A., aclinical stage product company specializing in the discovery anddevelopment of drugs for diseases of the nervous system, todayannounced that the Phase IIa clinical trial results of its s...

Cogane Data Presented at ‘11th International Congress of Parkinson’s Disease and Disorders’

GODMANCHESTER, England - (5 June 2007) -Phytopharm plc (LSE: PYM) ("Phytopharm" or the "Company") announcestoday pre-clinical data showing that Cogane(tm) reverses thechanges in the area of the brain involved in Parkinson's disease.This data will be presented by Dr Jonathan Brotchie, aninternationally recognised expert on Parkinson's disease at 'The11th International Congres...

Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard Researcher

STANFORD, Calif.--(BUSINESS WIRE)--May 30, 2007 - People with aclass of rare genetic disorders that often lead to brain damage,coma and death can be successfully treated with drugs, says aresearcher at the Stanford University School of Medicine and LucilePackard Children's Hospital. The researchers found in their unprecedented 25-year study thatprompt diagnosis coupled with a rapid start...

New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder

- Data Presented at 2007 APA Meeting - COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ -- Datafrom four new studies examining safety and efficacy ofdesvenlafaxine succinate, a serotonin-norepinephrine reuptakeinhibitor (SNRI) being studied as a potential treatment for adultswith major depressive disorder (MDD), were presented today at the2007 American Psychiatric Association annual...

Organon's Asenapine Effective in a Phase III Study for the Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA Meeting

SAN DIEGO, May 21, 2007 /PRNewswire/ -- Asenapine -- aninvestigational drug being developed by Organon, the humanhealthcare business unit of Akzo Nobel, for bipolar I disorder andschizophrenia -- was demonstrated to be more effective than placeboin treating acute manic and mixed episodes associated with bipolarI disorder, according to new Phase III results, from a studypresented at the A...

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

Pooled Findings Presented at 2007 APA Meeting Also Showed NoSignificant Impact on Weight for Desvenlafaxine Succinate COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ --Findings from two separate pooled analyses - one examining theeffect of desvenlafaxine succinate on anxious symptoms and theother on painful symptoms associated with major depressive disorder(MDD) -- as well as a sep...

Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants

- Results Presented at 160th Annual Meeting of the AmericanPsychiatric Association - SAN DIEGO, May 21, 2007 /PRNewswire-FirstCall/ -- In adults withmajor depressive disorder, adding aripiprazole to antidepressanttherapy (ADT) resulted in significant improvement in the primaryendpoint, the Montgomery- Asberg Depression Rating Scale (MADRS)Total Score. In this six-week, randomized, placebo...

Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder

Relationship Between Ability to Function and Treatment of Anxiousand Painful Physical Symptoms Studied INDIANAPOLIS, May 21, 2007 /PRNewswire-FirstCall/ -- Datasuggest that patients with generalized anxiety disorder (GAD)treated with Cymbalta(R) (duloxetine HCl) experienced improvedability to perform everyday activities at home, work and in socialsituations compared to sugar pill. These i...

Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter

BOSTON, April 25, 2007 /PRNewswire-USNewswire/ -- At leastone-third of the time, the symptoms of bipolar disorder firstappear in childhood or adolescence. However, in children, it can bedifficult to distinguish bipolar symptoms from those of otherdisorders, notes the May 2007 issue of the Harvard Mental HealthLetter. Children, especially young children, usually do not show theadul...

Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature

PTC124 Targets Nonsense Mutations; Addresses Underlying Cause ofGenetic Disorders and Restores Protein Function SOUTH PLAINFIELD, N.J., April 23, 2007 /PRNewswire/ -- Newpreclinical data published online in the current edition of thejournal Nature show that PTC124, an investigational new drugdesigned to bypass nonsense mutations, was efficacious in apreclinical model of Duchenne muscular...

Latest NIMH Study on Bipolar Disorder

Statement of Ken Duckworth, M.D., Medical Director NationalAlliance on Mental Illness (NAMI) ARLINGTON, Va., April 02, 2007 /PRNewswire-USNewswire/ -- Todaythe Archives of General Psychiatry published a study on theeffectiveness of psychosocial treatments for bipolar disorder,"Psychosocial Treatments for Bipolar Disorder." This is a follow upstudy to one released last Thursday in the New...

Study Sheds Light on Medication Treatment Options for Bipolar Disorder

BETHESDA, Md., March 29, 2007--For depressed people with bipolardisorder who are taking a mood stabilizer, adding an antidepressantmedication is no more effective than a placebo (sugar pill),according to results published online on March 28, 2007 in the NewEngland Journal of Medicine. The results are part of thelarge-scale, multi-site Systematic Treatment Enhancement Programfor Bipolar D...

Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder

National Autism Association calls 2006 Pediatrics study fatallyflawed CHICAGO, March 07, 2007 /PRNewswire-USNewswire/ -- New findingspresented yesterday at a National Autism Association meetingbolster claims that vaccines may play a role in the development ofautism spectrum disorders. David Ayoub, MD presented datasuggesting a correlation between mercury- containing vaccines andrates of...